A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

AIMS: Since 2006, DPP‐4 inhibitors have become established therapy for the treatment of type 2 diabetes. Despite sharing a common mechanism of action, considerable chemical diversity exists amongst members of the DPP‐4 inhibitor class, raising the question as to whether structural differences may re...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Joel P., SinhaRoy, Ranabir, Pocai, Alessandro, Kelly, Theresa M., Scapin, Giovanna, Gao, Ying‐Duo, Pryor, Kelly Ann D., Wu, Joseph K., Eiermann, George J., Xu, Shiyao S., Zhang, Xiaoping, Tatosian, Daniel A., Weber, Ann E., Thornberry, Nancy A., Carr, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360916/
https://www.ncbi.nlm.nih.gov/pubmed/30815539
http://dx.doi.org/10.1002/edm2.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360916/
https://www.ncbi.nlm.nih.gov/pubmed/30815539
http://dx.doi.org/10.1002/edm2.2

Ejemplares similares